DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Remdesivir |
DMBFZ6L
|
Moderate |
Increased risk of hepatotoxicity by the combination of Celecoxib and Remdesivir. |
1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]
|
[14] |
Repaglinide |
DM5SXUV
|
Moderate |
Increased risk of hypoglycemia by the combination of Celecoxib and Repaglinide. |
Acute diabete complication [5A2Y]
|
[15] |
Glibenclamide |
DM8JXPZ
|
Moderate |
Increased risk of hypoglycemia by the combination of Celecoxib and Glibenclamide. |
Acute diabete complication [5A2Y]
|
[15] |
Tolazamide |
DMIHRNA
|
Moderate |
Increased risk of hypoglycemia by the combination of Celecoxib and Tolazamide. |
Acute diabete complication [5A2Y]
|
[15] |
Nateglinide |
DMLK2QH
|
Moderate |
Increased risk of hypoglycemia by the combination of Celecoxib and Nateglinide. |
Acute diabete complication [5A2Y]
|
[15] |
Glipizide |
DMZA5PQ
|
Moderate |
Increased risk of hypoglycemia by the combination of Celecoxib and Glipizide. |
Acute diabete complication [5A2Y]
|
[15] |
Arn-509 |
DMT81LZ
|
Moderate |
Increased metabolism of Celecoxib caused by Arn-509 mediated induction of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[16] |
Oliceridine |
DM6MDCF
|
Moderate |
Decreased metabolism of Celecoxib caused by Oliceridine mediated inhibition of CYP450 enzyme. |
Acute pain [MG31]
|
[17] |
Galantamine |
DMEO794
|
Moderate |
Decreased metabolism of Celecoxib caused by Galantamine mediated inhibition of CYP450 enzyme. |
Alzheimer disease [8A20]
|
[18] |
Donepezil |
DMIYG7Z
|
Minor |
Decreased metabolism of Celecoxib caused by Donepezil mediated inhibition of CYP450 enzyme. |
Alzheimer disease [8A20]
|
[19] |
Metronidazole |
DMTIVEN
|
Moderate |
Decreased metabolism of Celecoxib caused by Metronidazole mediated inhibition of CYP450 enzyme. |
Amoebiasis [1A36]
|
[17] |
Inotersen |
DMJ93CT
|
Major |
Increased risk of nephrotoxicity by the combination of Celecoxib and Inotersen. |
Amyloidosis [5D00]
|
[16] |
Bedaquiline |
DM3906J
|
Moderate |
Increased risk of hepatotoxicity by the combination of Celecoxib and Bedaquiline. |
Antimicrobial drug resistance [MG50-MG52]
|
[20] |
Voriconazole |
DMAOL2S
|
Moderate |
Decreased metabolism of Celecoxib caused by Voriconazole mediated inhibition of CYP450 enzyme. |
Aspergillosis [1F20]
|
[14] |
Zafirlukast |
DMHNQOG
|
Moderate |
Decreased metabolism of Celecoxib caused by Zafirlukast mediated inhibition of CYP450 enzyme. |
Asthma [CA23]
|
[17] |
Budesonide |
DMJIBAW
|
Moderate |
Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Budesonide. |
Asthma [CA23]
|
[12] |
Desipramine |
DMT2FDC
|
Moderate |
Decreased metabolism of Celecoxib caused by Desipramine mediated inhibition of CYP450 enzyme. |
Attention deficit hyperactivity disorder [6A05]
|
[17] |
Ofloxacin |
DM0VQN3
|
Moderate |
Additive CNS depression effects by the combination of Celecoxib and Ofloxacin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
Kanamycin |
DM2DMPO
|
Moderate |
Increased risk of nephrotoxicity by the combination of Celecoxib and Kanamycin. |
Bacterial infection [1A00-1C4Z]
|
[22] |
Ciprofloxacin XR |
DM2NLS9
|
Moderate |
Additive CNS depression effects by the combination of Celecoxib and Ciprofloxacin XR. |
Bacterial infection [1A00-1C4Z]
|
[21] |
Trovafloxacin |
DM6AN32
|
Moderate |
Additive CNS depression effects by the combination of Celecoxib and Trovafloxacin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
Sulfamethoxazole |
DMB08GE
|
Moderate |
Decreased metabolism of Celecoxib caused by Sulfamethoxazole mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[17] |
Sparfloxacin |
DMB4HCT
|
Moderate |
Additive CNS depression effects by the combination of Celecoxib and Sparfloxacin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
Streptomycin |
DME1LQN
|
Moderate |
Increased risk of nephrotoxicity by the combination of Celecoxib and Streptomycin. |
Bacterial infection [1A00-1C4Z]
|
[22] |
Gemifloxacin |
DMHT34O
|
Moderate |
Additive CNS depression effects by the combination of Celecoxib and Gemifloxacin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
Norfloxacin |
DMIZ6W2
|
Moderate |
Additive CNS depression effects by the combination of Celecoxib and Norfloxacin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
ABT-492 |
DMJFD2I
|
Moderate |
Additive CNS depression effects by the combination of Celecoxib and ABT-492. |
Bacterial infection [1A00-1C4Z]
|
[21] |
Gentamicin |
DMKINJO
|
Moderate |
Increased risk of nephrotoxicity by the combination of Celecoxib and Gentamicin. |
Bacterial infection [1A00-1C4Z]
|
[22] |
Netilmicin |
DMRD1QK
|
Moderate |
Increased risk of nephrotoxicity by the combination of Celecoxib and Netilmicin. |
Bacterial infection [1A00-1C4Z]
|
[22] |
Levofloxacin |
DMS60RB
|
Moderate |
Additive CNS depression effects by the combination of Celecoxib and Levofloxacin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
Tobramycin |
DMUI0CH
|
Moderate |
Increased risk of nephrotoxicity by the combination of Celecoxib and Tobramycin. |
Bacterial infection [1A00-1C4Z]
|
[22] |
Lomefloxacin |
DMVRH9C
|
Moderate |
Additive CNS depression effects by the combination of Celecoxib and Lomefloxacin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
Etidronic acid |
DM1XHYJ
|
Moderate |
Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Etidronic acid. |
Bone paget disease [FB85]
|
[23] |
Risedronate |
DM5FLTY
|
Moderate |
Increased risk of nephrotoxicity by the combination of Celecoxib and Risedronate. |
Bone paget disease [FB85]
|
[23] |
Alendronate |
DMY2KX9
|
Moderate |
Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Alendronate. |
Bone paget disease [FB85]
|
[23] |
Pexidartinib |
DMS2J0Z
|
Major |
Increased risk of hepatotoxicity by the combination of Celecoxib and Pexidartinib. |
Bone/articular cartilage neoplasm [2F7B]
|
[24] |
Alpelisib |
DMEXMYK
|
Moderate |
Increased metabolism of Celecoxib caused by Alpelisib mediated induction of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[25] |
Tamoxifen |
DMLB0EZ
|
Major |
Decreased metabolism of Celecoxib caused by Tamoxifen mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[26] |
Iodipamide |
DMXIQYS
|
Major |
Increased risk of nephrotoxicity by the combination of Celecoxib and Iodipamide. |
Cholelithiasis [DC11]
|
[27] |
Dihydrocodeine |
DMB0FWL
|
Moderate |
Decreased metabolism of Celecoxib caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. |
Chronic pain [MG30]
|
[17] |
Anisindione |
DM2C48U
|
Moderate |
Increased plasma concentrations of Celecoxib and Anisindione due to competitive inhibition of the same metabolic pathway. |
Coagulation defect [3B10]
|
[28] |
Oxaliplatin |
DMQNWRD
|
Moderate |
Decreased renal excretion of Celecoxib caused by Oxaliplatin mediated nephrotoxicity. |
Colorectal cancer [2B91]
|
[29] |
Drospirenone |
DM1A9W3
|
Moderate |
Increased risk of hyperkalemia by the combination of Celecoxib and Drospirenone. |
Contraceptive management [QA21]
|
[30] |
Methoxyflurane |
DML0RAE
|
Moderate |
Increased risk of nephrotoxicity by the combination of Celecoxib and Methoxyflurane. |
Corneal disease [9A76-9A78]
|
[16] |
Dextromethorphan |
DMUDJZM
|
Moderate |
Decreased metabolism of Celecoxib caused by Dextromethorphan mediated inhibition of CYP450 enzyme. |
Cough [MD12]
|
[14] |
Mifepristone |
DMGZQEF
|
Moderate |
Decreased metabolism of Celecoxib caused by Mifepristone mediated inhibition of CYP450 enzyme. |
Cushing syndrome [5A70]
|
[31] |
Lumacaftor |
DMCLWDJ
|
Moderate |
Increased metabolism of Celecoxib caused by Lumacaftor mediated induction of CYP450 enzyme. |
Cystic fibrosis [CA25]
|
[32] |
Ivacaftor |
DMZC1HS
|
Moderate |
Decreased metabolism of Celecoxib caused by Ivacaftor mediated inhibition of CYP450 enzyme. |
Cystic fibrosis [CA25]
|
[33] |
MK-8228 |
DMOB58Q
|
Moderate |
Increased metabolism of Celecoxib caused by MK-8228 mediated induction of CYP450 enzyme. |
Cytomegaloviral disease [1D82]
|
[34] |
Aprepitant |
DM053KT
|
Moderate |
Increased metabolism of Celecoxib caused by Aprepitant mediated induction of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[35] |
Sertraline |
DM0FB1J
|
Moderate |
Decreased metabolism of Celecoxib caused by Sertraline mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[17] |
Trimipramine |
DM1SC8M
|
Moderate |
Decreased metabolism of Celecoxib caused by Trimipramine mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[17] |
Nortriptyline |
DM4KDYJ
|
Moderate |
Decreased metabolism of Celecoxib caused by Nortriptyline mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[17] |
Paroxetine |
DM5PVQE
|
Moderate |
Decreased metabolism of Celecoxib caused by Paroxetine mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[17] |
OPC-34712 |
DMHG57U
|
Major |
Decreased metabolism of Celecoxib caused by OPC-34712 mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[36] |
Clomipramine |
DMINRKW
|
Moderate |
Decreased metabolism of Celecoxib caused by Clomipramine mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[17] |
Trazodone |
DMK1GBJ
|
Moderate |
Decreased metabolism of Celecoxib caused by Trazodone mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[17] |
Amoxapine |
DMKITQE
|
Moderate |
Decreased metabolism of Celecoxib caused by Amoxapine mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[17] |
Doxepin |
DMPI98T
|
Moderate |
Decreased metabolism of Celecoxib caused by Doxepin mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[17] |
Maprotiline |
DMPWB7T
|
Moderate |
Decreased metabolism of Celecoxib caused by Maprotiline mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[17] |
Fenfluramine |
DM0762O
|
Moderate |
Decreased metabolism of Celecoxib caused by Fenfluramine mediated inhibition of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[17] |
Cannabidiol |
DM0659E
|
Moderate |
Increased risk of hepatotoxicity by the combination of Celecoxib and Cannabidiol. |
Epileptic encephalopathy [8A62]
|
[16] |
Ethacrynic acid |
DM60QMR
|
Moderate |
Antagonize the effect of Celecoxib when combined with Ethacrynic acid. |
Essential hypertension [BA00]
|
[37] |
Benzthiazide |
DMQWZ0H
|
Moderate |
Antagonize the effect of Celecoxib when combined with Benzthiazide. |
Essential hypertension [BA00]
|
[37] |
Tolterodine |
DMSHPW8
|
Minor |
Decreased metabolism of Celecoxib caused by Tolterodine mediated inhibition of CYP450 enzyme. |
Functional bladder disorder [GC50]
|
[38] |
Darifenacin |
DMWXLYZ
|
Moderate |
Decreased metabolism of Celecoxib caused by Darifenacin mediated inhibition of CYP450 enzyme. |
Functional bladder disorder [GC50]
|
[39] |
Miconazole |
DMPMYE8
|
Moderate |
Decreased metabolism of Celecoxib caused by Miconazole mediated inhibition of CYP450 enzyme. |
Fungal infection [1F29-1F2F]
|
[17] |
Cimetidine |
DMH61ZB
|
Moderate |
Decreased metabolism of Celecoxib caused by Cimetidine mediated inhibition of CYP450 enzyme. |
Gastro-oesophageal reflux disease [DA22]
|
[17] |
Eplerenone |
DMF0NQR
|
Moderate |
Increased risk of hyperkalemia by the combination of Celecoxib and Eplerenone. |
Heart failure [BD10-BD1Z]
|
[40] |
Carvedilol |
DMHTEAO
|
Moderate |
Decreased metabolism of Celecoxib caused by Carvedilol mediated inhibition of CYP450 enzyme. |
Heart failure [BD10-BD1Z]
|
[17] |
Chlorothiazide |
DMLHESP
|
Moderate |
Antagonize the effect of Celecoxib when combined with Chlorothiazide. |
Heart failure [BD10-BD1Z]
|
[37] |
Furosemide |
DMMQ8ZG
|
Moderate |
Antagonize the effect of Celecoxib when combined with Furosemide. |
Heart failure [BD10-BD1Z]
|
[37] |
Amiloride |
DMRTSGP
|
Moderate |
Antagonize the effect of Celecoxib when combined with Amiloride. |
Heart failure [BD10-BD1Z]
|
[37] |
Bumetanide |
DMRV7H0
|
Moderate |
Antagonize the effect of Celecoxib when combined with Bumetanide. |
Heart failure [BD10-BD1Z]
|
[37] |
Hydroflumethiazide |
DMVPUQI
|
Moderate |
Antagonize the effect of Celecoxib when combined with Hydroflumethiazide. |
Heart failure [BD10-BD1Z]
|
[37] |
Isoniazid |
DM5JVS3
|
Moderate |
Decreased metabolism of Celecoxib caused by Isoniazid mediated inhibition of CYP450 enzyme. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[17] |
Rifampin |
DMA8J1G
|
Moderate |
Increased metabolism of Celecoxib caused by Rifampin mediated induction of CYP450 enzyme. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[41] |
Rifapentine |
DMCHV4I
|
Moderate |
Increased metabolism of Celecoxib caused by Rifapentine mediated induction of CYP450 enzyme. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[42] |
Brentuximab vedotin |
DMWLC57
|
Moderate |
Increased risk of hepatotoxicity by the combination of Celecoxib and Brentuximab vedotin. |
Hodgkin lymphoma [2B30]
|
[43] |
Delavirdine |
DM3NF5G
|
Minor |
Decreased metabolism of Celecoxib caused by Delavirdine mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[17] |
Efavirenz |
DMC0GSJ
|
Moderate |
Decreased metabolism of Celecoxib caused by Efavirenz mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[17] |
Etravirine |
DMGV8QU
|
Moderate |
Decreased metabolism of Celecoxib caused by Etravirine mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[44] |
Gemfibrozil |
DMD8Q3J
|
Moderate |
Decreased metabolism of Celecoxib caused by Gemfibrozil mediated inhibition of CYP450 enzyme. |
Hyper-lipoproteinaemia [5C80]
|
[17] |
Fenofibrate |
DMFKXDY
|
Moderate |
Decreased metabolism of Celecoxib caused by Fenofibrate mediated inhibition of CYP450 enzyme. |
Hyper-lipoproteinaemia [5C80]
|
[14] |
Mipomersen |
DMGSRN1
|
Major |
Increased risk of hepatotoxicity by the combination of Celecoxib and Mipomersen. |
Hyper-lipoproteinaemia [5C80]
|
[45] |
Teriflunomide |
DMQ2FKJ
|
Major |
Increased risk of hepatotoxicity by the combination of Celecoxib and Teriflunomide. |
Hyper-lipoproteinaemia [5C80]
|
[13] |
BMS-201038 |
DMQTAGO
|
Major |
Increased risk of hepatotoxicity by the combination of Celecoxib and BMS-201038. |
Hyper-lipoproteinaemia [5C80]
|
[46] |
Penbutolol |
DM4ES8F
|
Moderate |
Decreased metabolism of Celecoxib caused by Penbutolol mediated inhibition of CYP450 enzyme. |
Hypertension [BA00-BA04]
|
[17] |
Nebivolol |
DM7F1PA
|
Moderate |
Decreased metabolism of Celecoxib caused by Nebivolol mediated inhibition of CYP450 enzyme. |
Hypertension [BA00-BA04]
|
[17] |
Indapamide |
DMGN1PW
|
Moderate |
Antagonize the effect of Celecoxib when combined with Indapamide. |
Hypertension [BA00-BA04]
|
[37] |
Trichlormethiazide |
DMHAQCO
|
Moderate |
Antagonize the effect of Celecoxib when combined with Trichlormethiazide. |
Hypertension [BA00-BA04]
|
[37] |
Labetalol |
DMK8U72
|
Moderate |
Decreased metabolism of Celecoxib caused by Labetalol mediated inhibition of CYP450 enzyme. |
Hypertension [BA00-BA04]
|
[17] |
Hydrochlorothiazide |
DMUSZHD
|
Moderate |
Antagonize the effect of Celecoxib when combined with Hydrochlorothiazide. |
Hypertension [BA00-BA04]
|
[37] |
Fludrocortisone |
DMUDIR8
|
Moderate |
Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Fludrocortisone. |
Hypo-osmolality/hyponatraemia [5C72]
|
[12] |
Balsalazide |
DM7I1T9
|
Moderate |
Increased risk of nephrotoxicity by the combination of Celecoxib and Balsalazide. |
Indeterminate colitis [DD72]
|
[11] |
Propiomazine |
DMKY8V1
|
Moderate |
Decreased metabolism of Celecoxib caused by Propiomazine mediated inhibition of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[17] |
Methotrexate |
DM2TEOL
|
Moderate |
Increased risk of hepatotoxicity by the combination of Celecoxib and Methotrexate. |
Leukaemia [2A60-2B33]
|
[16] |
Ibandronate |
DM0QZBN
|
Moderate |
Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Ibandronate. |
Low bone mass disorder [FB83]
|
[16] |
Porfimer Sodium |
DM7ZWNY
|
Moderate |
Increased risk of photosensitivity reactions by the combination of Celecoxib and Porfimer Sodium. |
Lung cancer [2C25]
|
[47] |
PF-06463922 |
DMKM7EW
|
Moderate |
Increased metabolism of Celecoxib caused by PF-06463922 mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[14] |
Chloroquine |
DMSI5CB
|
Moderate |
Decreased metabolism of Celecoxib caused by Chloroquine mediated inhibition of CYP450 enzyme. |
Malaria [1F40-1F45]
|
[17] |
Primaquine |
DMWQ16I
|
Moderate |
Decreased metabolism of Celecoxib caused by Primaquine mediated inhibition of CYP450 enzyme. |
Malaria [1F40-1F45]
|
[17] |
Calaspargase pegol |
DMQZBXI
|
Moderate |
Increased risk of hepatotoxicity by the combination of Celecoxib and Calaspargase pegol. |
Malignant haematopoietic neoplasm [2B33]
|
[48] |
Idelalisib |
DM602WT
|
Moderate |
Increased risk of hepatotoxicity by the combination of Celecoxib and Idelalisib. |
Mature B-cell leukaemia [2A82]
|
[49] |
Clofarabine |
DMCVJ86
|
Moderate |
Increased risk of nephrotoxicity by the combination of Celecoxib and Clofarabine. |
Mature B-cell lymphoma [2A85]
|
[16] |
Dabrafenib |
DMX6OE3
|
Moderate |
Increased metabolism of Celecoxib caused by Dabrafenib mediated induction of CYP450 enzyme. |
Melanoma [2C30]
|
[16] |
Propranolol |
DM79NTF
|
Moderate |
Decreased metabolism of Celecoxib caused by Propranolol mediated inhibition of CYP450 enzyme. |
Migraine [8A80]
|
[17] |
Exjade |
DMHPRWG
|
Major |
Increased risk of nephrotoxicity by the combination of Celecoxib and Exjade. |
Mineral absorption/transport disorder [5C64]
|
[50] |
Deflazacort |
DMV0RNS
|
Moderate |
Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Deflazacort. |
Muscular dystrophy [8C70]
|
[12] |
Methoxsalen |
DME8FZ9
|
Moderate |
Increased risk of photosensitivity reactions by the combination of Celecoxib and Methoxsalen. |
Mycosis fungoides [2B01]
|
[14] |
Imatinib |
DM7RJXL
|
Moderate |
Decreased metabolism of Celecoxib caused by Imatinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[51] |
Promethazine |
DM6I5GR
|
Moderate |
Decreased metabolism of Celecoxib caused by Promethazine mediated inhibition of CYP450 enzyme. |
Nausea/vomiting [MD90]
|
[17] |
Ondansetron |
DMOTQ1I
|
Moderate |
Decreased metabolism of Celecoxib caused by Ondansetron mediated inhibition of CYP450 enzyme. |
Nausea/vomiting [MD90]
|
[17] |
Dexfenfluramine |
DMJ7YDS
|
Moderate |
Decreased metabolism of Celecoxib caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. |
Obesity [5B80-5B81]
|
[17] |
Metolazone |
DMB39LO
|
Moderate |
Antagonize the effect of Celecoxib when combined with Metolazone. |
Oedema [MG29]
|
[37] |
Polythiazide |
DMCH80F
|
Moderate |
Antagonize the effect of Celecoxib when combined with Polythiazide. |
Oedema [MG29]
|
[37] |
Diclofenac |
DMPIHLS
|
Moderate |
Increased risk of hepatotoxicity by the combination of Celecoxib and Diclofenac. |
Osteoarthritis [FA00-FA05]
|
[52] |
Rucaparib |
DM9PVX8
|
Moderate |
Decreased metabolism of Celecoxib caused by Rucaparib mediated inhibition of CYP450 enzyme. |
Ovarian cancer [2C73]
|
[53] |
Pentazocine |
DM1XBHS
|
Moderate |
Decreased metabolism of Celecoxib caused by Pentazocine mediated inhibition of CYP450 enzyme. |
Pain [MG30-MG3Z]
|
[17] |
Dextropropoxyphene |
DM23HCX
|
Moderate |
Decreased metabolism of Celecoxib caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme. |
Pain [MG30-MG3Z]
|
[17] |
Aspirin |
DM672AH
|
Moderate |
Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Aspirin. |
Pain [MG30-MG3Z]
|
[54] |
Methamphetamine |
DMPM4SK
|
Moderate |
Decreased metabolism of Celecoxib caused by Methamphetamine mediated inhibition of CYP450 enzyme. |
Pain [MG30-MG3Z]
|
[17] |
Hydrocodone |
DMQ2JO5
|
Moderate |
Decreased metabolism of Celecoxib caused by Hydrocodone mediated inhibition of CYP450 enzyme. |
Pain [MG30-MG3Z]
|
[17] |
Oxycodone |
DMXLKHV
|
Moderate |
Decreased metabolism of Celecoxib caused by Oxycodone mediated inhibition of CYP450 enzyme. |
Pain [MG30-MG3Z]
|
[17] |
Prednisone |
DM2HG4X
|
Moderate |
Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Prednisone. |
Postoperative inflammation [1A00-CA43]
|
[12] |
Hydrocortisone |
DMGEMB7
|
Moderate |
Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Hydrocortisone. |
Postoperative inflammation [1A00-CA43]
|
[12] |
Enzalutamide |
DMGL19D
|
Moderate |
Increased metabolism of Celecoxib caused by Enzalutamide mediated induction of CYP450 enzyme. |
Prostate cancer [2C82]
|
[55] |
Tamsulosin |
DM5QF9V
|
Moderate |
Decreased metabolism of Celecoxib caused by Tamsulosin mediated inhibition of CYP450 enzyme. |
Prostate hyperplasia [GA90]
|
[56] |
Levomepromazine |
DMIKFEL
|
Moderate |
Decreased metabolism of Celecoxib caused by Levomepromazine mediated inhibition of CYP450 enzyme. |
Psychotic disorder [6A20-6A25]
|
[17] |
Fluphenazine |
DMIT8LX
|
Moderate |
Decreased metabolism of Celecoxib caused by Fluphenazine mediated inhibition of CYP450 enzyme. |
Psychotic disorder [6A20-6A25]
|
[17] |
Triflupromazine |
DMKFQJP
|
Moderate |
Decreased metabolism of Celecoxib caused by Triflupromazine mediated inhibition of CYP450 enzyme. |
Psychotic disorder [6A20-6A25]
|
[17] |
Bosentan |
DMIOGBU
|
Moderate |
Increased metabolism of Celecoxib caused by Bosentan mediated induction of CYP450 enzyme. |
Pulmonary hypertension [BB01]
|
[57] |
Everolimus |
DM8X2EH
|
Major |
Increased risk of nephrotoxicity by the combination of Celecoxib and Everolimus. |
Renal cell carcinoma [2C90]
|
[58] |
Temsirolimus |
DMS104F
|
Major |
Increased risk of nephrotoxicity by the combination of Celecoxib and Temsirolimus. |
Renal cell carcinoma [2C90]
|
[58] |
Gatifloxacin |
DMSL679
|
Moderate |
Additive CNS depression effects by the combination of Celecoxib and Gatifloxacin. |
Respiratory infection [CA07-CA4Z]
|
[21] |
Oxamniquine |
DM2QDX1
|
Moderate |
Decreased metabolism of Celecoxib caused by Oxamniquine mediated inhibition of CYP450 enzyme. |
Schistosomiasis [1F86]
|
[17] |
Mesoridazine |
DM2ZGAN
|
Moderate |
Decreased metabolism of Celecoxib caused by Mesoridazine mediated inhibition of CYP450 enzyme. |
Schizophrenia [6A20]
|
[17] |
Thioridazine |
DM35M8J
|
Major |
Decreased metabolism of Celecoxib caused by Thioridazine mediated inhibition of CYP450 enzyme. |
Schizophrenia [6A20]
|
[59] |
Aripiprazole |
DM3NUMH
|
Moderate |
Decreased metabolism of Celecoxib caused by Aripiprazole mediated inhibition of CYP450 enzyme. |
Schizophrenia [6A20]
|
[60] |
Haloperidol |
DM96SE0
|
Moderate |
Decreased metabolism of Celecoxib caused by Haloperidol mediated inhibition of CYP450 enzyme. |
Schizophrenia [6A20]
|
[17] |
Perphenazine |
DMA4MRX
|
Moderate |
Decreased metabolism of Celecoxib caused by Perphenazine mediated inhibition of CYP450 enzyme. |
Schizophrenia [6A20]
|
[17] |
Trifluoperazine |
DMKBYWI
|
Moderate |
Decreased metabolism of Celecoxib caused by Trifluoperazine mediated inhibition of CYP450 enzyme. |
Schizophrenia [6A20]
|
[17] |
Risperidone |
DMN6DXL
|
Moderate |
Decreased metabolism of Celecoxib caused by Risperidone mediated inhibition of CYP450 enzyme. |
Schizophrenia [6A20]
|
[17] |
Pimozide |
DMW83TP
|
Major |
Decreased metabolism of Celecoxib caused by Pimozide mediated inhibition of CYP450 enzyme. |
Schizophrenia [6A20]
|
[61] |
Methylprednisolone |
DM4BDON
|
Moderate |
Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Methylprednisolone. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Trabectedin |
DMG3Y89
|
Moderate |
Increased risk of hepatotoxicity by the combination of Celecoxib and Trabectedin. |
Solid tumour/cancer [2A00-2F9Z]
|
[16] |
Prednisolone |
DMQ8FR2
|
Moderate |
Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Prednisolone. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Pitolisant |
DM8RFNJ
|
Moderate |
Decreased metabolism of Celecoxib caused by Pitolisant mediated inhibition of CYP450 enzyme. |
Somnolence [MG42]
|
[16] |
Disulfiram |
DMCL2OK
|
Moderate |
Decreased metabolism of Celecoxib caused by Disulfiram mediated inhibition of CYP450 enzyme. |
Substance abuse [6C40]
|
[17] |
Naltrexone |
DMUL45H
|
Moderate |
Increased risk of hepatotoxicity by the combination of Celecoxib and Naltrexone. |
Substance abuse [6C40]
|
[62] |
Warfarin |
DMJYCVW
|
Moderate |
Increased plasma concentrations of Celecoxib and Warfarin due to competitive inhibition of the same metabolic pathway. |
Supraventricular tachyarrhythmia [BC81]
|
[28] |
Sirolimus |
DMGW1ID
|
Major |
Increased risk of nephrotoxicity by the combination of Celecoxib and Sirolimus. |
Transplant rejection [NE84]
|
[58] |
Tacrolimus |
DMZ7XNQ
|
Major |
Increased risk of nephrotoxicity by the combination of Celecoxib and Tacrolimus. |
Transplant rejection [NE84]
|
[58] |
Tolbutamide |
DM02AWV
|
Moderate |
Increased risk of hypoglycemia by the combination of Celecoxib and Tolbutamide. |
Type 2 diabetes mellitus [5A11]
|
[15] |
Chlorpropamide |
DMPHZQE
|
Moderate |
Increased risk of hypoglycemia by the combination of Celecoxib and Chlorpropamide. |
Type 2 diabetes mellitus [5A11]
|
[15] |
Olsalazine |
DMZW9HA
|
Moderate |
Increased risk of nephrotoxicity by the combination of Celecoxib and Olsalazine. |
Ulcerative colitis [DD71]
|
[11] |
Cinoxacin |
DM4EWNS
|
Moderate |
Additive CNS depression effects by the combination of Celecoxib and Cinoxacin. |
Urinary tract infection [GC08]
|
[21] |
Sulfamethizole |
DMGCHDS
|
Moderate |
Decreased metabolism of Celecoxib caused by Sulfamethizole mediated inhibition of CYP450 enzyme. |
Urinary tract infection [GC08]
|
[17] |
Plazomicin |
DMKMBES
|
Moderate |
Increased risk of nephrotoxicity by the combination of Celecoxib and Plazomicin. |
Urinary tract infection [GC08]
|
[22] |
Nalidixic acid |
DMRM0JV
|
Moderate |
Additive CNS depression effects by the combination of Celecoxib and Nalidixic acid. |
Urinary tract infection [GC08]
|
[21] |
Triamcinolone |
DM98IXF
|
Moderate |
Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Triamcinolone. |
Vasomotor/allergic rhinitis [CA08]
|
[12] |
Methdilazine |
DMAUHQX
|
Moderate |
Decreased metabolism of Celecoxib caused by Methdilazine mediated inhibition of CYP450 enzyme. |
Vasomotor/allergic rhinitis [CA08]
|
[17] |
Trimeprazine |
DMEMV9D
|
Moderate |
Decreased metabolism of Celecoxib caused by Trimeprazine mediated inhibition of CYP450 enzyme. |
Vasomotor/allergic rhinitis [CA08]
|
[17] |
Propafenone |
DMPIBJK
|
Moderate |
Decreased metabolism of Celecoxib caused by Propafenone mediated inhibition of CYP450 enzyme. |
Ventricular tachyarrhythmia [BC71]
|
[17] |
Flecainide |
DMSQDLE
|
Moderate |
Decreased metabolism of Celecoxib caused by Flecainide mediated inhibition of CYP450 enzyme. |
Ventricular tachyarrhythmia [BC71]
|
[17] |
Amiodarone |
DMUTEX3
|
Moderate |
Decreased metabolism of Celecoxib caused by Amiodarone mediated inhibition of CYP450 enzyme. |
Ventricular tachyarrhythmia [BC71]
|
[17] |
----------- |
|
|
|
|
|